{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:43:11Z","timestamp":1764175391673},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,9,1]]},"DOI":"10.2169\/internalmedicine.0539-22","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T22:11:50Z","timestamp":1675203110000},"page":"2553-2557","source":"Crossref","is-referenced-by-count":3,"title":["Aplastic Anemia with Epstein-Barr Virus Reactivation after Anti-thymocyte Globulin Therapy"],"prefix":"10.2169","volume":"62","author":[{"given":"Yo","family":"Kawarada","sequence":"first","affiliation":[{"name":"Department of Hematology, Ebina General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryujiro","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ebina General Hospital, Japan"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Kitahara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ebina General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Numata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ebina General Hospital, Japan"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ebina General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Histopathology, Ebina General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Mashima K, Yano S, Yokoyama H, et al. Epstein-Barr virus-associated lymphoproliferative disorder with encephalitis following anti-thymocyte globulin for aplastic anemia resolved with rituximab therapy: a case report and literature review. Intern Med 56: 701-706, 2017.","DOI":"10.2169\/internalmedicine.56.7722"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Shimizu H, Kobayashi N, Mihara M, et al. Successful treatment of Epstein-Barr virus-associated lymphoproliferative disorder with rituximab in a patient undergoing immunosuppressive therapy for aplastic anemia. Acta Haematol 136: 174-177, 2016.","DOI":"10.1159\/000447420"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tsukamoto S, Nagao Y, Yamazaki A, et al. Successful allogeneic stem cell transplantation for severe aplastic anemia after treatment of lymphoproliferative disorder caused by rabbit antithymocyte globulin. Intern Med 54: 3197-3200, 2015.","DOI":"10.2169\/internalmedicine.54.5090"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Takahashi T, Maruyama Y, Saitoh M, et al. Fatal Epstein-Barr virus reactivation in an acquired aplastic anemia patient treated with rabbit antithymocyte globulin and cyclosporine A. Case Rep Hematol 2015: 926874, 2015.","DOI":"10.1155\/2015\/926874"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hanaoka N, Murata S, Hosoi H, et al. B-cell-rich T-cell lymphoma associated with Epstein-Barr virus-reactivation and T-cell suppression following antithymocyte globulin therapy in a patient with severe aplastic anemia. Hematol Rep 7: 5906, 2015.","DOI":"10.4081\/hr.2015.5906"},{"key":"6","unstructured":"6. Nakanishi R, Ishida M, Hodohara K, et al. Occurrence of Epstein-Barr virus-associated plasmacytic lymphoproliferative disorder after antithymocyte globulin therapy for aplastic anemia: a case report with review of the literature. Int J Clin Exp Pathol 7: 1748-1754, 2014."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sugimoto-Sekiguchi H, Tashiro H, Shirasaki R, et al. Colonic EBV-associated lymphoproliferative disorder in a patient treated with rabbit antithymocyte globulin for aplastic anemia. Case Rep Gastrointest Med 2012: 395801, 2012.","DOI":"10.1155\/2012\/395801"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ohata K, Iwaki N, Kotani T, et al. An Epstein-Barr virus-associated leukemic lymphoma in a patient treated with rabbit antithymocyte globulin and cyclosporine for hepatitis-associated aplastic anemia. Acta Haematol 127: 96-99, 2012.","DOI":"10.1159\/000333609"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Viola GM, Zu Y, Baker KR, Aslam S. Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy. Med Oncol 28: 1604-1608, 2011.","DOI":"10.1007\/s12032-010-9635-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Suzuki Y, Niitsu N, Hayama M, et al. Lymphoproliferative disorders after immunosuppressive therapy for aplastic anemia: a case report and literature review. Acta Haematol 121: 21-26, 2009.","DOI":"10.1159\/000209225"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Wondergem MJ, Stevens SJ, Janssen JJ, et al. Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression. Blood 111: 1739, 2008.","DOI":"10.1182\/blood-2007-09-111534"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Potenza L, Barozzi P, Codeluppi M, et al. Epstein-Barr virus associated pneumonia in an adult patient with severe aplastic anaemia: resolution after the transient withdrawal of cyclosporine. Am J Hematol 82: 944-946, 2007.","DOI":"10.1002\/ajh.20950"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Calistri E, Tiribelli M, Battista M, et al. Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia. Am J Hematol 81: 355-357, 2006.","DOI":"10.1002\/ajh.20560"},{"key":"14","unstructured":"14. Raghavachar A, Ganser A, Freund M, et al. Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia. Cytokines Mol Ther 2: 215-223, 1996."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Dorr V, Doolittle G, Woodroof J. First report of a B cell lymphoproliferative disorder arising in a patient treated with immune suppressants for severe aplastic anemia. Am J Hematol 52: 108-113, 1996.","DOI":"10.1002\/(SICI)1096-8652(199606)52:2<108::AID-AJH7>3.0.CO;2-Y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cesaro S, Murrone A, Mengoli C, et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 128: 224-233, 2005.","DOI":"10.1111\/j.1365-2141.2004.05287.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the second European Conference on Infections in leukemia. Bone Marrow Transplant 43: 757-770, 2009.","DOI":"10.1038\/bmt.2008.386"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 98: 972-978, 2001.","DOI":"10.1182\/blood.V98.4.972"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hoshino Y, Kimura H, Tanaka N, et al. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. Br J Haematol 115: 105-111, 2001.","DOI":"10.1046\/j.1365-2141.2001.03087.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Rooney CM, Loftin SK, Holladay MS, et al. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 89: 98-103, 1995.","DOI":"10.1111\/j.1365-2141.1995.tb08904.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 23: 7574-7582, 2005.","DOI":"10.1200\/JCO.2005.01.0934"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Corey L, Beyrer C, Cohen MS, et al. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med 385: 562-566, 2021.","DOI":"10.1056\/NEJMsb2104756"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Yasuda H, Tsukune Y, Watanabe N, et al. Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clin Lymphoma Myeloma Leuk 20: 774-776, 2020.","DOI":"10.1016\/j.clml.2020.08.017"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kos I, Balensiefer B, Roth S, et al. Prolonged course of COVID-19-associated pneumonia in a B-cell depleted patient after rituximab. Front Oncol 10: 1578, 2020.","DOI":"10.3389\/fonc.2020.01578"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/17\/62_0539-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:28:32Z","timestamp":1715574512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/17\/62_0539-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":24,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0539-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"article-number":"0539-22"}}